查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800209

主动式植入式医疗设备(AIMD) 市场 - 2025 年至 2030 年预测

Active Implantable Medical Devices (AIMD) Market - Forecasts fom 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

主动植入式医疗设备(AIMD) 市场预计将从 2025 年的 351.95 亿美元成长到 2030 年的 491.97 亿美元，复合年增长率为 6.93%。

受技术进步、人口老化和慢性病盛行率上升的推动，全球有源植入式医疗设备(AIMD) 市场正在经历显着成长。心律调节器和神经刺激设备等 AIMD 对于监测和治疗疾病至关重要，尤其对于老年人。

市场驱动因素

1. 老化社会中慢性病盛行率上升：老年人中心血管疾病、糖尿病和神经系统疾病等慢性病盛行率的上升是AIMD市场的主要驱动力。这些设备在管理复杂的医疗保健需求、改善患者预后和提高生活品质方面发挥着至关重要的作用。全球老年人口的成长推动了对AIMD的需求，医疗保健提供者正在寻求先进的解决方案来应对与老龄化相关的健康挑战。

2. 技术进步与人工智慧整合：AIMD 技术的创新，例如将人工智慧 (AI) 整合用于患者专属诊断，正在推动市场成长。 AI 设备正在提高监测准确性和治疗效果，促进其广泛应用。持续的研发和现有 AIMD 适应症的扩展，进一步推动了技术创新，为市场持续成长奠定了基础。

3. 政府政策与资金支持：韩国《医疗设备产业培育及创新医疗设备扶持法》等监管架构正在促进AIMD的发展。政府资金以及人们对AIMD益处的认知度不断提升，推动了AIMD研发和产品上市的投资，从而支持了市场扩张。

市场限制

1.高成本和监管挑战：AIMD 的开发和製造成本高昂，加上严格的监管要求，对市场成长构成挑战。遵守不同的全球标准会增加製造成本和时间，这可能会限制其在成本敏感型市场的普及。

2. 新兴市场认知度低：儘管需求不断成长，但某些地区（尤其是新兴经济体）对AIMD益处的认知度较低，这可能会阻碍市场渗透。向医疗保健专业人员和患者普及AIMD的益处仍然是一项重大挑战。

区域展望

  • 北美（美国）：受心血管疾病高发生率的推动，美国预计将占据最大的市场占有率。根据世界银行的数据，到2022年，老龄化人口将占美国总人口的17%，这将进一步推动对AIMD的需求。雅培实验室的AVEIR™双腔心律调节器（已于2023年7月获得FDA核准）等技术进步将透过提供针对心律不整的创新解决方案来推动市场成长。
  • 亚太地区：在印度等慢性病负担沉重的国家（根据美国国家医学图书馆的数据，21% 的老年人受慢性病影响），对AIMD的需求正在增加。支持性法律规范和医疗基础设施投资正在推动该地区的成长。

关键发展（2023-2025年）

  • 2023 年 7 月：雅培实验室的 AVEIR™ 双腔心律调节器获得美国FDA核准，扩大了美国心率患者的治疗选择。

市场展望

预计到2025年，AIMD市场将迎来强劲成长，这得益于慢性病负担的增加、技术进步以及扶持政策的推动。美国由于人口老化和疾病高发生率而引领市场，但亚太地区也蕴藏着巨大的潜力。为了保持成长，需要应对高成本和监管复杂性等挑战。预计产业参与者将专注于整合人工智慧并产品推出，以满足不断变化的医疗保健需求。

本报告的主要优点

  • 深刻分析：获得深入的市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采用的策略策略，并了解正确策略的市场渗透潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力进行策略决策并在动态环境中开闢新的业务流和收益。
  • 适合广泛的使用者：对于新兴企业、研究机构、顾问、中小企业和大型企业来说都是有益且具有成本效益的。

它有什么用途？

产业与市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2020 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测细分市场和区域分析（包括国家）
  • 公司概况（尤其是趋势）、财务资讯和关键发展。

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

5. 主动式植入式医疗设备(AIMD) 市场（依产品）

  • 介绍
  • 心室辅助装置
  • 神经刺激设备
  • 植入式心臟节律器
  • 人工电子耳
  • 其他的

6. 主动式植入式医疗设备(AIMD) 市场（依最终用户）

  • 介绍
  • 医院和诊所
  • 门诊手术中心
  • 专业中心
  • 居家照护环境

7. 主动式植入式医疗设备(AIMD) 市场（按地区）

  • 介绍
  • 北美洲
    • 按产品
    • 按最终用户
    • 按国家
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按产品
    • 按最终用户
    • 按国家
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 按产品
    • 按最终用户
    • 按国家
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 按产品
    • 按最终用户
    • 按国家
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 按产品
    • 按最终用户
    • 按国家
      • 中国
      • 日本
      • 印度
      • 韩国
      • 台湾
      • 其他的

第八章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章：公司简介

  • Sonova Holding AG
  • Medtronic
  • Abbott
  • Lifetech Scientific
  • Boston Scientific Corporation
  • Cochlear Ltd.
  • MED-EL
  • Biotronik SE & Co. KG
  • LivaNova PLC

第十章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061611637

The Active Implantable Medical Devices (AIMD) Market is expected to grow from USD 35.195 billion in 2025 to USD 49.197 billion in 2030, at a CAGR of 6.93%.

The global active implantable medical devices (AIMD) market is experiencing significant growth, driven by technological advancements, an aging population, and the rising prevalence of chronic diseases. AIMDs, such as pacemakers and neurostimulators, are critical for monitoring and treating conditions, particularly in geriatric patients.

Market Drivers

1. Rising Prevalence of Chronic Diseases in the Aging Population: The growing incidence of chronic conditions, such as cardiovascular diseases, diabetes, and neurological disorders, among older adults is a primary driver of the AIMD market. These devices play a vital role in managing complex healthcare needs, improving patient outcomes, and enhancing quality of life. The increasing elderly population globally amplifies demand for AIMDs, as healthcare providers seek advanced solutions to address age-related health challenges.

2. Technological Advancements and AI Integration: Innovations in AIMD technology, including the integration of artificial intelligence (AI) for patient-specific diagnostics, are propelling market growth. AI-enabled devices enhance monitoring precision and treatment efficacy, driving adoption. Ongoing research and development, along with expanded indications for existing AIMDs, further fuel innovation, positioning the market for sustained growth.

3. Supportive Government Policies and Funding: Regulatory frameworks, such as the Republic of Korea's Act on Fostering the Medical Devices Industry and Supporting Innovative Medical Devices, are fostering AIMD development. Government funding and increased awareness of AIMD benefits are encouraging investment in research and product launches, supporting market expansion.

Market Restraints

1. High Costs and Regulatory Challenges: The high cost of developing and manufacturing AIMDs, coupled with stringent regulatory requirements, poses challenges to market growth. Compliance with diverse global standards increases production costs and timelines, potentially limiting accessibility in cost-sensitive markets.

2. Limited Awareness in Emerging Markets: Despite growing demand, limited awareness of AIMD benefits in certain regions, particularly in developing economies, may hinder market penetration. Educating healthcare providers and patients about the advantages of AIMDs remains a critical challenge.

Geographical Outlook

  • North America (United States): The U.S. is expected to hold the largest market share, driven by the high prevalence of cardiovascular diseases. The aging population, representing 17% of the U.S. population in 2022 per World Bank data, further boosts demand for AIMDs. Technological advancements, such as Abbott Laboratories' FDA-approved AVEIR(TM) dual-chamber pacemaker in July 2023, enhance market growth by offering innovative solutions for heart rhythm disorders.
  • Asia-Pacific: Countries like India, with a high burden of chronic diseases (21% of the elderly affected, per the National Library of Medicine), are seeing increased demand for AIMDs. Supportive regulatory frameworks and investments in healthcare infrastructure are driving growth in this region.

Key Developments (2023-2025)

  • July 2023: Abbott Laboratories received U.S. FDA approval for its AVEIR(TM) dual-chamber pacemaker, expanding treatment options for patients with abnormal heart rhythms in the U.S.

Market Outlook

The AIMD market is poised for robust growth through 2025, driven by the rising burden of chronic diseases, technological advancements, and supportive policies. The U.S. leads due to its aging population and high disease prevalence, while Asia-Pacific shows strong potential. Challenges such as high costs and regulatory complexities must be addressed to sustain growth. Industry players are expected to focus on AI integration and innovative product launches to meet evolving healthcare demands.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2020 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Active Implantable Medical Devices (AIMD) Market Segmentation:

By Product

  • Ventricular Assist Devices
  • Neurostimulators
  • Implantable Cardiac Pacemakers
  • Cochlear Implants
  • Others

By End-User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Specialty Centers
  • Home Care Settings

By Geography

  • North America
  • South America
  • Europe
  • Middle East and Africa
  • Asia Pacific

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ACTIVE IMPLANTABLE MEDICAL DEVICES (AIMD) MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Ventricular Assist Devices
  • 5.3. Neurostimulators
  • 5.4. Implantable Cardiac Pacemakers
  • 5.5. Cochlear Implants
  • 5.6. Others

6. ACTIVE IMPLANTABLE MEDICAL DEVICES (AIMD) MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Hospitals & Clinics
  • 6.3. Ambulatory Surgical Centers
  • 6.4. Specialty Centers
  • 6.5. Home Care Settings

7. ACTIVE IMPLANTABLE MEDICAL DEVICES (AIMD) MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Product
    • 7.2.2. By End-User
    • 7.2.3. By Country
      • 7.2.3.1. USA
      • 7.2.3.2. Canada
      • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Product
    • 7.3.2. By End-User
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
      • 7.3.3.2. Argentina
      • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Product
    • 7.4.2. By End-User
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
      • 7.4.3.2. Germany
      • 7.4.3.3. France
      • 7.4.3.4. Spain
      • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Product
    • 7.5.2. By End-User
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
      • 7.5.3.2. UAE
      • 7.5.3.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Product
    • 7.6.2. By End-User
    • 7.6.3. By Country
      • 7.6.3.1. China
      • 7.6.3.2. Japan
      • 7.6.3.3. India
      • 7.6.3.4. South Korea
      • 7.6.3.5. Taiwan
      • 7.6.3.6. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Sonova Holding AG
  • 9.2. Medtronic
  • 9.3. Abbott
  • 9.4. Lifetech Scientific
  • 9.5. Boston Scientific Corporation
  • 9.6. Cochlear Ltd.
  • 9.7. MED-EL
  • 9.8. Biotronik SE & Co. KG
  • 9.9. LivaNova PLC

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key Benefits for the Stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations